Amrutanjan Health Care Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Amrutanjan Health Care's board approved audited results for Q4 and FY ended March 31, 2025. FY25 revenue from operations rose to Rs. 45,181.63 lakhs from Rs. 42,123.05 lakhs (up about 7.3%), while profit after tax grew to Rs. 5,083.47 lakhs from Rs. 4,497.26 lakhs (up about 13%), with EPS at Rs. 17.58 vs Rs. 15.50. Q4 revenue came in at Rs. 13,541.36 lakhs and Q4 PAT at Rs. 1,517.78 lakhs. The board recommended a final dividend of Rs. 2.60 per share, taking total FY25 dividend to Rs. 3.60 per share (including Rs. 1 interim already paid). Statutory auditor BSR & Co. LLP issued an unmodified opinion.
Steady mid-single-digit revenue growth and low-teens PAT growth, combined with a consistent dividend, suggest a stable, shareholder-friendly year; however, the Women's Hygiene segment continues to post segment-level losses, which is a watchpoint for future quarters.